Progesterone Receptor Antagonists and Selective Progesterone Receptor Modulators (SPRMs)

Irving M. Spitz

doi:10.1055/s-2005-864029

Seminars in Reproductive Medicine, Table of Contents

Semin Reprod Med 2005; 23(1): 3-7
DOI: 10.1055/s-2005-864029

Preface

Progesterone Receptor Antagonists and Selective Progesterone Receptor Modulators (SPRMs)

Irving M. Spitz¹ Guest Editors

¹Institute of Hormone Research, Shaare Zedek Medical Center, Jerusalem, Israel; and Weill Medical College of Cornell University, New York, New York. E-mail: irving@spitz.com

Abstract

Full Text

References

REFERENCES

1 Fraenkel L, Cohn F. Experimentalle Untersuchung uber den Einfluss des Corpus luteum of die Insertion des Eies. Anat Anz. 1901; 20 294-300
2 Butenandt A, Wesphal U, Hohlweg W. Uber das Hormon des Corpus luteum. Z Physiol Chem. 1934; 227 84-98
3 Allen W M, Wintersteiner O. Crystalline progesterone. Science. 1934; 80 190-191
4 Slotta K H, Ruschig H, Fels E. Teindarstellung der Hormon aus dem Corpus-luteum. Ber Chem Ges. 1934; 67 1270-1273
5 Hartmann M, Wettstein A. Ein krystallisiertes Hormon aus Corpus-luteum. Helv Chim Acta. 1934; 17 878-882
6 O'Malley B W, McGuire W L, Kohler P O, Korenman S G. Studies on the mechanism of steroid hormone regulation of synthesis of specific proteins. Recent Prog Horm Res. 1969; 25 105-160
7 Milgrom E, Atger M, Baulieu E E. Progesterone in uterus and plasma. IV: Progesterone receptor(s) in guinea pig uterus cytosol. Steroids. 1970; 16 741-754
8 Philibert D, Deraedt R, Teutsch G. RU 38486: a potent antiglucocorticoid in vivo. Paper presented at the VII International Congress of Pharmacology 1981 Tokyo, Japan;
9 Philibert D. RU38486: an original multifaceted antihormone in vivo. In: Agarwal M Adrenal Steroid Antagonism Berlin; Walter de Gruyter 1984: 77-101
10 Csapo A I. The prospects of PGs in postconceptional therapy. Prostaglandins. 1973; 3 245-289
11 Herrmann W, Wyss R, Riondel A et al.. The effects of an antiprogesterone steroid in women: interruption of the menstrual cycle and of early pregnancy. C R Seances Acad Sci III. 1982; 294 933-938
12 Christin-Maitre S, Bouchard P, Spitz I M. Medical termination of pregnancy. N Engl J Med. 2000; 342 946-956
13 Elger W, Beier S, Chwalisz K et al.. Studies on the mechanisms of action of progesterone antagonists. J Steroid Biochem. 1986; 25 835-845
14 Swahn M L, Bygdeman M. The effect of the antiprogestin RU 486 on uterine contractility and sensitivity to prostaglandin and oxytocin. Br J Obstet Gynaecol. 1988; 95 126-134
15 Schrader W T, O'Malley B W. Progesterone-binding components of chick oviduct. IV. Characterization of purified subunits. J Biol Chem. 1972; 247 51-59
16 Leonhardt S A, Edwards D P. Mechanism of action of progesterone antagonists. Exp Biol Med (Maywood). 2002; 227 969-980
17 McDonnell D P, Goldman M E. RU486 exerts antiestrogenic activities through a novel progesterone receptor A form-mediated mechanism. J Biol Chem. 1994; 269 11945-11949
18 Lydon J P, DeMayo F J, Funk C R et al.. Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev. 1995; 9 2266-2278
19 Onate S A, Tsai S Y, Tsai M J, O'Malley B W. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science. 1995; 270 1354-1357
20 Cavailles V, Dauvois S, L'Horset F et al.. Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor. EMBO J. 1995; 14 3741-3751
21 Schena M, Shalon D, Davis R W, Brown P O. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science. 1995; 270 467-470
22 Cheon Y P, Li Q, Xu X et al.. A genomic approach to identify novel progesterone receptor regulated pathways in the uterus during implantation. Mol Endocrinol. 2002; 16 2853-2871
23 Wolf J P, Hsiu J G, Anderson T L et al.. Noncompetitive antiestrogenic effect of RU 486 in blocking the estrogen-stimulated luteinizing hormone surge and the proliferative action of estradiol on endometrium in castrate monkeys. Fertil Steril. 1989; 52 1055-1060
24 Hodgen G D, van Uem J F, Chillik C F et al.. Non-competitive anti-oestrogenic activity of progesterone antagonists in primate models. Hum Reprod. 1994; 9(suppl 1) 77-81
25 Slayden O D, Brenner R M. RU 486 action after estrogen priming in the endometrium and oviducts of rhesus monkeys (Macaca mulatta). J Clin Endocrinol Metab. 1994; 78 440-448
26 Smith C L, O'Malley B W. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev. 2004; 25 45-71
27 McPhail M K. The assay of progestin. J Physiol. 1934; 83 145-156
28 Elger W, Bartley J, Schneider B et al.. Endocrine pharmacological characterization of progesterone antagonists and progesterone receptor modulators with respect to PR-agonistic and antagonistic activity. Steroids. 2000; 65 713-723
29 DeManno D, Elger W, Garg R et al.. Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy. Steroids. 2003; 68 1019-1032
30 Newfield R S, Spitz I M, Isacson C, New M I. Long-term mifepristone (RU486) therapy resulting in massive benign endometrial hyperplasia. Clin Endocrinol (Oxf). 2001; 54 399-404
31 Martineau P A, Levental M. Large endometrial polyp in a patient on long-term mifepristone therapy. J Ultrasound Med. 2000; 19 487-489
32 Eisinger S H, Meldrum S, Fiscella K, le Roux H D, Guzick D S. Low-dose mifepristone for uterine leiomyomata. Obstet Gynecol. 2003; 101 243-250
33 Spitz I M. Progesterone antagonists and progesterone receptor modulators: an overview. Steroids. 2003; 68 981-993
34 Chwalisz K, DeManno D, Garg R et al.. Therapeutic potential for the selective progesterone receptor modulator asoprisnil in the treatment of leiomyomata. Semin Reprod Med. 2004; 22 113-119